Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257462 · ClinicalTrials.gov registry record · Phase 2
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
A Phase 2 study, sponsored by Spruce Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03257462 is a Phase 2 study that has completed, run by Spruce Biosciences. The registered enrollment target is 24 participants.
The verdict
NCT03257462, a Phase 2 study, has completed, sponsored by Spruce Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).
Interventions
- DRUG SPR001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257462
The ClinicalTrials.gov registry entry for NCT03257462 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spruce Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPR001 is the first listed.
NCT03257462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03257462 about?
NCT03257462 is a clinical study titled "Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia". This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with classic congenital adrenal hyperplasia (CAH).
What is the current status of trial NCT03257462?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2017-07-12. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03257462?
The interventions under investigation include: SPR001 (DRUG).
Who is sponsoring clinical trial NCT03257462?
This trial is sponsored by Spruce Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.